Why the study?
Does percutaneous left atrial appendage transcatheter occlusion improve safety and prevent thromboembolic events in patients with chronic nonvalvular atrial fibrillation contraindicated for oral anticoagulation?
Does percutaneous left atrial appendage transcatheter occlusion improve safety and prevent thromboembolic events in patients with chronic nonvalvular atrial fibrillation contraindicated for oral anticoagulation?
Answers are grounded in this paper and cite their sources.
Percutaneous left atrial appendage occlusion is safe and feasible in patients with nonvalvular atrial fibrillation who are ineligible for oral anticoagulation.
OBJECTIVE: The percutaneous left atrial appendage transcatheter occlusion system (PLAATO, ev3 Inc., Plymouth, Minnesota, USA) is a novel technique of interventional cardiology, which has recently been proposed for the nonpharmacological prophylaxis of thromboembolic events in patients with chronic nonvalvular atrial fibrillation ineligible for oral anticoagulation therapy with vitamin K antagonists. The aim of this study was to assess the safety, feasibility and mid-term efficacy of this procedure. METHODS: We conducted a preliminary institutional experience on a selected population of seven patients (two male, five female, mean age 64 +/- 7 years) with chronic nonvalvular atrial fibrillation at high risk for thromboembolic events with contraindications for oral anticoagulation therapy with vitamin K antagonists. RESULTS: All procedures were successfully performed without any complications at a mean follow-up of 7 +/- 4 months and no thromboembolic or adverse cardiac events occurred. CONCLUSIONS: Percutaneous left atrial appendage transcatheter occlusion is safe and feasible, without any complications at mid-term follow-up.
No takes yet. Share an insight, caveat, or question.
Ussia et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: